• Seeking Alpha

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Seeking Alpha / 17 hours ago 2 Views

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye

Read more
  • Source:
  • GlobeNewswire - News about Public Companies
Previous post
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Next post
Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

Comments

Just Posted

  • Share Buyback Transaction Details July 3 – July 9, 2025

    3 hours from now

  • Bourse Direct Horizon décroche à nouveau le LABEL D’EXCELLENCE 2025 !

    3 hours from now

  • Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

    3 hours from now

  • Form 8.5 (EPT/RI)-Ricardo plc

    3 hours from now

  • Man Group PLC : Form 8.3 - American Axle & Manufacturing Holdings, Inc.

    3 hours from now

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Reviews

Categories

  • Seeking Alpha 1077

Categories

  • Seeking Alpha 1077

Pages

Tags

  • SA Transcripts
  • TOU:CA
  • Gold Mining Bull
  • TPZ
  • NG1:COM
  • CHK
  • TRMLF
  • fivn
  • CGIFF
  • CHE.UN:CA

Copyright News That Move � 2018. All Rights Reserved

  • Seeking Alpha
  • Trade Halts